• Search
  • Helpdesk
  • Sales contact

biotech

Expanding investor confidence: The strategic value of Patient Reported Outcomes (PROs) in biotech fundraising

For biotech companies engaged in the clinical development of a therapeutic innovation, securing investor trust is as critical as demonstrating the scientific value of their molecule. One powerful yet underleveraged...

Leveraging the potential of Patient Reported Outcome (PRO) data to accelerate therapeutic innovation market access

Patients Reported Outcome (PRO) data provide information on patient health that is obtained directly from the patient.PRO measures serve to...

Innovation and Partnerships: The Biotech Perspective

In the ever-evolving landscape of biotechnology, groundbreaking advancements continue to shape the future of healthcare. In this exclusive interview, Estelle...

Emerging Biopharma & Biotech (EBP) – 5 key success factors for your clinical trials

With so much at stake, consider partnering with an eCOA and DCT expert!Kayentis offers a unified platform featuring trustworthy services...
Follow us on social media
Subscribe to our newsletter
About the author